DE2139183A1 - Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid - Google Patents

Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid

Info

Publication number
DE2139183A1
DE2139183A1 DE19712139183 DE2139183A DE2139183A1 DE 2139183 A1 DE2139183 A1 DE 2139183A1 DE 19712139183 DE19712139183 DE 19712139183 DE 2139183 A DE2139183 A DE 2139183A DE 2139183 A1 DE2139183 A1 DE 2139183A1
Authority
DE
Germany
Prior art keywords
monophosphoric acid
contg
compsns
addns
pharm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19712139183
Other languages
German (de)
Inventor
Boris Dr Janistyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LINGNER WERKE GmbH
Original Assignee
LINGNER WERKE GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LINGNER WERKE GmbH filed Critical LINGNER WERKE GmbH
Priority to DE19712139183 priority Critical patent/DE2139183A1/en
Publication of DE2139183A1 publication Critical patent/DE2139183A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • A61K8/606Nucleosides; Nucleotides; Nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The activity of title compsns. contg. hormones, anabolic steroids, vitamins et al. is protracted by the addn. of cyclic adenosine-monophosphoric acid (c-AMP) and derivs. including the cyclic guanosine-monophosphoric acid which exhibit a strictly local effect e.g. on the skin.

Description

Beschreibung Kosmetische und pharmazeutische Zuboreitungen Die kosmetischen (und pharmazeutischen) Präparate, die u.s. Hormone (Östrogene, Gestagene, Androgene usw.), anabolische Steroide und/oder Vitamine und Vitaminoide authalten, haben oft eine unsichere Wirkung. Es wurde nun gefunden, dass die wirkung der genannten Stoffs signifikant protahiert wird, kann den kosmetischen und pharmazeutischen Präproten "cyclische Adenosinmonophosphorsäure"(Adenosin-3,54 monophosphorsäure cyclisch ; c-AMP) oder deren Derivate bzw .verwandte Verbindungen, beispielsweise cycl. Dibutyryl-3,5'-adanosinphosphorsäure, Dibutyryl-gunanesin-3,5-monophosphorsäure cyclisch oder die Monobutyrylverbindungen in .-orm der Säute bzw.deren Salze zugesetzt werden.Die Butyrylgruppen erhöhen die Ed@@löslichkeit und sie können durch Valerylgruppen oder andere Gruppen ersetzt werden. Description Cosmetic and pharmaceutical accessories The cosmetic (and pharmaceutical) preparations containing u.s. Hormones (estrogens, progestins, androgens etc.), anabolic steroids and / or vitamins and vitaminoids are often used an uncertain effect. It has now been found that the effect of the substance mentioned The cosmetic and pharmaceutical preproteins can be significantly protahed "cyclic adenosine monophosphoric acid" (adenosine-3.54 monophosphoric acid cyclic; c-AMP) or their derivatives or related compounds, for example cycl. Dibutyryl-3,5'-adanosine phosphoric acid, Dibutyryl-gunanesin-3,5-monophosphoric acid cyclic or the monobutyryl compounds in. -orm of the acids or their salts. The butyryl groups increase the Ed @@ solubility and they can be replaced by valeryl groups or other groups will.

Da die c-2MP kaum permeabel ist und ebnso wenig die Alkalisalze ist so bsmerkenswert, dass die Alkylolaminsalse nennenswert parpeabel sind, wes einen Fort ohritt in der Anwendung bedeutet.Since the c-2MP is hardly permeable and the alkali salts are just as little so remarkable that the alkylolamine salts are appreciably parpeable, which is one of them Continuing in the application means.

Dis Zusammensetzung der Kosmetika ist die übliche, sie können glüssig bi cremeförmig sein.The composition of cosmetics is the usual, they can be smooth bi be creamy.

is wislfältigen physiologischen Wirkungen der c-AMP sind bekennt und die Adenosintriphosphate bzw.die Salze wurden bereits für Kosmetika empfohlen;sie sind nicht permeabel und haben nicht die breite Wirkung der c-AMP oder deren Derivate. The wise physiological effects of c-AMP are known and the adenosine triphosphates or salts have already been recommended for cosmetics; they are not permeable and do not have the broad effect of c-AMP or its derivatives.

als sogenannter sekundärer Massenger(@second messenger") leitet en zellspesifische hormonale Informationen, wolche vermutlich @@ defür geignete Rezsptoren der Zallmembran angrofien im Zellinnern weiter. Le lässt sich beispielsweise die Wirkung des adreaccorticotropen @ormens (ACTI) auf die nebennierenrinde (z.B.Cortiostaroid-Ausschüttung) durch lokale Applikation von c-AMP ersetzen.as a so-called secondary masseger (@second messenger ") leads en Cell-specific hormonal information, presumably want @@ for suitable receptors the cell membrane continued to grow inside the cell. Le can, for example, the Effect of the adreaccorticotropic norm (ACTI) on the adrenal cortex (e.g. cortiostaroid secretion) Replace with local application of c-AMP.

de vielen Untersuchungen der latzten dahre haben gezeigt, dass @@ c-AMP eine wegentliche Rolle bei der Enzymaktiviorung und Zellwundpermcabilitätsänderungen im Zellstoffwechsel spielt. Frst die Anspr@@it von c-AMP ermöglicht die lebensnotwendigen Transpiption (@NA-<R@A) und damit auch die Translation (@@@-< Prot@in). de many studies in the last few years have shown that @@ c-AMP plays an important role in enzyme activation and changes in cellular wound permeability in cell metabolism. The c-AMP request enables the vital transpcription (@ NA- <R @ A) and thus also the translation (@@@ - <Prot @ in).

Versuche an den enthsarten Flanken von Mcerschweinchen mit einer O/W-Emulsion mit c-AMP(Colaminsalz) und c-Dibutyryl-AMP ergab Akanthose der Haut und dautliche Proliforation. Die Befunde wur den bei Zusatz von anabolischen Steroiden noch verbessert und diese konnten in den Mengen geminlert werden. Darin ist ein beachtlicher technischer Vorteil zu erblicken,denn viele anabolischen Steroide sind physiologisch nicht so harmlos als in der Literatur dargestellt (Nabensffekte).Zu erwähnen sind u.a.Ethisteron, api-Androsterdn.Experiments on the dehumidified flanks of McPigs with an O / W emulsion with c-AMP (colamine salt) and c-dibutyryl-AMP resulted in acanthosis of the skin and similar Proliferation. The findings were improved with the addition of anabolic steroids and these could be reduced in quantity. There is a considerable technical in it Advantage to see, as many anabolic steroids are physiologically not like that harmless than presented in the literature (hub effects), such as ethisterone, api-Androsterdn.

in erheblicher Vorteil besteht auch darin,dass die c-AMP und D-rivate streng lokale Wirkungen am Zielorgan, also bier der Haut entfalten. Sie vermag nicht event.nachteilig in den Gesamtatoffwechsel einzugreifen, wie das bei Östrogenen zu befürchten ist.There is also a considerable advantage in the fact that the c-AMP and D-derivatives Strictly develop local effects on the target organ, i.e. on the skin. She cannot possibly interfering adversely with the overall metabolism, as is the case with estrogens is to be feared.

Durch die c-AMT bzw. Derivaten ist en möglich den Energiestoffwechsel der Zelle äusserlich massgeblich zu beeinflussen.The c-AMT or derivatives enable the energy metabolism to influence the cell externally significantly.

Disse Eigenschaften machen die c-AMP und Derivate au cinem wichtigen Bestandteil zahlreicher kosmetischer und/oder pharmazeutischen Zubereitungen.These properties make the c-AMP and derivatives also important Component of numerous cosmetic and / or pharmaceutical preparations.

Beispiele: Hasrwasser: 55,0 Äthanol oder Igopropanol 44,0 Wasser, destilliert 0,2 Panthenol 0,2 Salicylsäure 0,05 Laurylpyridiniumchlorid 0,1 Camphersäure 0,2 Dipropylenglykol 01 Polyvinylpyrrolidon rein 0r25 Riechstoffe 5 -50 mg Dibutyrul-adenosin-3,5-monophesphat-Colaminsalz cycl.Examples: Hasr water: 55.0 ethanol or Igopropanol 44.0 water, distilled 0.2 panthenol 0.2 salicylic acid 0.05 laurylpyridinium chloride 0.1 camphoric acid 0.2 dipropylene glycol 01 polyvinylpyrrolidone pure 0r25 fragrances 5 - 50 mg dibutyrul-adenosine-3,5-monophesphate-colamine salt cycl.

+ 10 -100 mg c-AMP -alkylolaminsalz je 1000 ml Bautoremo : 10,0 Paraffinöl, niedrigviskos 5,0 Erdnussöl, konserviert 8,0 Miglyol 812 (ein Triglycerid) 7,0 Ischexadecylisostcarat 2,0 Lanolinöl, hell 9,0 @achsemulgator mit Tensiden 3,0 Glycerin IAB 7 0,2 Chloracetamid 0,5 magnesiumsulfat kristallisiert 53,0 @@sser, desstillier56t 2,0 Citratpuffer (pH-5,5-6,5); 1,10-3 molar 5 - 50 mg c-Dibutyl-AMP-aminsalz + (oder) 10-100 mg c- AMP je 1 kg Emulsion Herstellung : Die Emulsion wird bei etda 75-80° be Berücksichtigte Literatur: I. Karlson: irkungsmechanismen der Hormone. 18.Coll.d.Ges. + 10 -100 mg c-AMP -alkylolamine salt per 1000 ml Bautoremo: 10.0 paraffin oil, Low viscosity 5.0 Peanut oil, preserved 8.0 Miglyol 812 (a triglyceride) 7.0 Ischexadecyl isostcarate 2.0 Lanolin oil, light 9.0 Axial emulsifier with surfactants 3.0 Glycerin IAB 7 0.2 Chloracetamide 0.5 magnesium sulfate crystallizes 53.0 @@ sser, desstillier56t 2.0 citrate buffer (pH 5.5-6.5); 1.10-3 molar 5 - 50 mg c-dibutyl-AMP-amine salt + (or) 10-100 mg c- AMP per 1 kg of emulsion Production: The emulsion is at around 75-80 ° Considered Literature: I. Karlson: mechanisms of action of the hormones. 18.Coll.d.Ges.

f. Physiol. Chemie. Mosbach 1967. Springer-Verlag, Berlin 1967 W. Blech: Die biochem. Wirkungsweise der Hormone. Naturwiss. f. Physiol. Chemistry. Mosbach 1967. Springer-Verlag, Berlin 1967 W. Blech: The biochem. How the hormones work. Natural science

Rdsch. 11, 459(1968) E.J.V.J. Christ: Fette-Seifen-Anstrichmittel 10, 849 ( 14. Tausk: Pharmakologie der Hormone.Georg Thieme Verlag (1970) J. Pastan u. R.L. Perlmann: Cyclic AMP in Metabolism. Rdsch. 11, 459 (1968) E.J.V.J. Christ: Fette-Soap-Paint 10, 849 (14. Tausk: Pharmakologie der Hormone. Georg Thieme Verlag (1970) J. Pastan u. R.L. Perlmann: Cyclic AMP in Metabolism.

Nature New Biology Vol. 229 Jan.6 ; p.5 (1971) R.C. Haymes, S.B.Koritz u.F.O.Peron: J.Biol.Chem.234,1421 (1959) @.@. Sutherland, R.W. Butcher, G.A. Robison, I.G.Hardman: The role of adenosin-3,5'-monophosphat in hormone action. Aus: (1).S.1 Y. Oshima, T.Horiuchi, Y.Iida u.T. Kameyama. Mol.Gen.Genetics 106, 307 (1970) E. Böhme, K.Munske u.G.Schultz. Nannyn-Schmiedebergs Arch. Nature New Biology Vol. 229 Jan.6; p.5 (1971) R.C. Haymes, S.B. Koritz u.F.O. Peron: J.Biol.Chem. 234, 1421 (1959) @. @. Sutherland, R.W. Butcher, G.A. Robison, I.G. Hardman: The role of adenosine-3,5'-monophosphate in hormone action. From: (1) .S.1 Y. Oshima, T. Horiuchi, Y.Iida & T. Kameyama. Mol. Gen. Genetics 106, 307 (1970) E. Böhme, K. Munske and G. Schulz. Nannyn-Schmiedeberg's Arch.

Pbarmakol. 264, 220 (1969) J.F. Kuo, J.Sanes u.P.Greengard. Federation Proceedings 29, 1990(1970) Pbarmakol. 264, 220 (1969) J.F. Kuo, J. Sanes, and P. Greengard. Federation Proceedings 29, 1990 (1970)

Claims (1)

Patentanspruch: Dosmetische und/oder pharmazeutische Zubereitungen dadurch gekennzeichnet, dass ihnen cyclische Adenosinmonophosphorsäure und deren Derivate einschliesslich der cyclischen Guanosinmonophosphorsäure und ähnlicher Derivate zugesetzt werden.Claim: Cosmetic and / or pharmaceutical preparations characterized in that they cyclic adenosine monophosphoric acid and their Derivatives including cyclic guanosine monophosphoric acid and the like Derivatives are added.
DE19712139183 1971-08-05 1971-08-05 Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid Pending DE2139183A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19712139183 DE2139183A1 (en) 1971-08-05 1971-08-05 Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19712139183 DE2139183A1 (en) 1971-08-05 1971-08-05 Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid

Publications (1)

Publication Number Publication Date
DE2139183A1 true DE2139183A1 (en) 1973-02-15

Family

ID=5815851

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19712139183 Pending DE2139183A1 (en) 1971-08-05 1971-08-05 Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid

Country Status (1)

Country Link
DE (1) DE2139183A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256472A2 (en) * 1986-08-11 1988-02-24 Lion Corporation Cosmetic agent for application to skin
EP0260697A2 (en) 1986-09-18 1988-03-23 Lion Corporation Composition for application to hair
JPS63183518A (en) * 1986-09-18 1988-07-28 Lion Corp Composition for hair
EP0332847A2 (en) * 1988-03-16 1989-09-20 Lion Corporation Composition for preventing graying of the hair and restoring grayed hair to its natural color
EP0435180A1 (en) * 1989-12-27 1991-07-03 Lion Corporation Composition for treating hair
US5185150A (en) * 1990-08-24 1993-02-09 Wisconsin Alumni Research Fdn. Cosmetic compositions containing 19-nor-vitamin D compounds
US5376643A (en) * 1986-09-18 1994-12-27 Lion Corporation Composition for application to hair

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256472A2 (en) * 1986-08-11 1988-02-24 Lion Corporation Cosmetic agent for application to skin
EP0256472A3 (en) * 1986-08-11 1988-09-07 Lion Corporation Cosmetic agent for application to skin
EP0260697A2 (en) 1986-09-18 1988-03-23 Lion Corporation Composition for application to hair
JPS63183518A (en) * 1986-09-18 1988-07-28 Lion Corp Composition for hair
EP0260697A3 (en) * 1986-09-18 1988-08-31 Lion Corporation Composition for application to hair
US5376643A (en) * 1986-09-18 1994-12-27 Lion Corporation Composition for application to hair
EP0332847A2 (en) * 1988-03-16 1989-09-20 Lion Corporation Composition for preventing graying of the hair and restoring grayed hair to its natural color
EP0332847A3 (en) * 1988-03-16 1990-04-11 Lion Corporation Composition for preventing graying of the hair and restoring grayed hair to its natural color
EP0435180A1 (en) * 1989-12-27 1991-07-03 Lion Corporation Composition for treating hair
US5185150A (en) * 1990-08-24 1993-02-09 Wisconsin Alumni Research Fdn. Cosmetic compositions containing 19-nor-vitamin D compounds

Similar Documents

Publication Publication Date Title
EP0291863B1 (en) Mixed crystals of insulin and insulin derivatives, their process of manufacture and pharmaceutical agents containing them
KR930012013A (en) Pharmaceutical ingredients used topically to treat psoriasis and irritable dermatitis
DE2139183A1 (en) Sustained action cosmetic and/or pharm compsns - contg addns of cyclic adenosine-monophosphoric acid
DE2124752A1 (en) Process for the production of a diagnostic preparation based on macroaggregates of serum protein labeled with 99mTc
DE2610020A1 (en) PHARMACEUTICAL COMPOSITION
DE2164052A1 (en) COSMETIC AGENTS WITH NUCLEOSIDE DERIVATIVES
DE2920020C2 (en)
GB1356635A (en) Deodorising and anti-seborrhoeic compositions
DE1617871A1 (en) Process for the production of a stable aqueous solution
DE2551480C3 (en) Technetium-99m-labeled kidney diagnostic and process for its preparation
DE1142428B (en) Skin and hair care products
DE1642612A1 (en) The use of erythrocytes to obtain or isolate a plasminogen activator
CH676424A5 (en)
EP0003041B1 (en) Technetium-99m marked diagnostic composition for the representation of the reticuloendothelial system (res) and process for its preparation
DE940060C (en) Process for the production of aqueous solutions of drugs that are poorly soluble in water
Berrens et al. Preparation and properties of purified house dust allergen
DE2725765A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING THIAZOLE DERIVATIVES
DE3216026A1 (en) TECHNETIUM (99M) MARKED ISONICOTINIC HYDRAZIDE, METHOD FOR THE PRODUCTION THEREOF AND A PHARMACEUTICAL AGENT CONTAINING THIS COMPOUND
DE1692463A1 (en) Stimulant for the growth and development of animals and poultry and processes for the production thereof
EP0108248B2 (en) Aqueous nitroglycerine solution free of solubilizers
DE930171C (en) Process for the production of aqueous solutions of steroid hormones
DE967872C (en) Process for the production of aqueous solutions of drugs that are poorly soluble in water
DE925541C (en) Process for the production of aqueous solutions of drugs that are poorly soluble in water
DE801839C (en) Process for preparing an organic salt of ª-methylmercapto-ª-aminobutyric acid
AT345482B (en) PROCESS FOR THE PRODUCTION OF NEW INSULIN DERIVATIVES